Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 258

1.

Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.

Zhang YX, Wang L, Ji PY, Zhao GG, Zhong GP, Wang ZP.

Arch Med Res. 2013 May;44(4):259-65. doi: 10.1016/j.arcmed.2013.03.008. Epub 2013 May 22.

PMID:
23707648
2.

IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.

Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.

Eur Urol. 2006 Feb;49(2):286-92; discussion 292. Epub 2005 Dec 7.

PMID:
16386354
4.

Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.

García-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L, Musquera M, Franco A, Alvarez-Vijande R, Ribal MJ, Alcaraz A.

BJU Int. 2012 Dec;110(11 Pt B):E541-6. doi: 10.1111/j.1464-410X.2012.11232.x. Epub 2012 May 15.

5.
6.

Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.

Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG.

Br J Cancer. 2002 Sep 23;87(7):726-8.

7.

Progression of prostate cancer: diagnostic and prognostic utility of prostate-specific antigen, alpha2-macroglobulin, and their complexes.

Kanoh Y, Ohtani N, Ohara T, Mashiko T, Ohtani S, Egawa S, Baba S, Ohtani H.

Oncol Rep. 2001 May-Jun;8(3):515-9.

PMID:
11295072
8.

Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.

Stamey TA, Ekman PE, Blankenstein MA, Cooper EH, Kontturi M, Lilja H, Oesterling JE, Stenman UH, Turkes A.

Scand J Urol Nephrol Suppl. 1994;162:73-87; discussion 115-27. Review.

PMID:
7529430
9.

Serum levels of secreted group IIA phospholipase A(2) in benign prostatic hyperplasia and prostate cancer: a biomarker for inflammation or neoplasia?

Menschikowski M, Hagelgans A, Fuessel S, Mareninova OA, Neumeister V, Wirth MP, Siegert G.

Inflammation. 2012 Jun;35(3):1113-8. doi: 10.1007/s10753-011-9418-1.

PMID:
22189868
10.

Impact of prostate-specific antigen density in benign prostatic hyperplasia and prostate carcinoma. Preliminary results.

Akdaş A, Dillioğlugil O, Cevik I, Ilker Y.

Eur Urol. 1994;25(4):299-303; discussion 304.

PMID:
7519992
11.

The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.

Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.

Cancer. 1998 Dec 15;83(12):2540-7.

PMID:
9874461
12.

[The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].

Hirao Y, Ozono S, Kagebayashi Y, Yoshi M, Tani Y, Uemura H, Momose H, Okajima E.

Hinyokika Kiyo. 1996 Oct;42(10):795-804. Japanese.

13.

Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.

Tilli TM, Thuler LC, Matos AR, Coutinho-Camillo CM, Soares FA, da Silva EA, Neves AF, Goulart LR, Gimba ER.

Exp Mol Pathol. 2012 Feb;92(1):13-9. doi: 10.1016/j.yexmp.2011.09.014. Epub 2011 Sep 22.

PMID:
21963599
14.

Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.

Zagars GK, Pollack A, von Eschenbach AC.

Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):23-35.

PMID:
7543892
15.

Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.

Michael A, Stephan C, Kristiansen G, Burckhardt M, Loening SA, Schnorr D, Jung K.

Prostate. 2005 Jan 1;62(1):34-9.

PMID:
15389818
16.

Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.

Miyamoto S, Ito K, Miyakubo M, Suzuki R, Yamamoto T, Suzuki K, Suzuki K, Yamanaka H.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):75-86. doi: 10.1038/pcan.2011.47. Epub 2011 Oct 11.

PMID:
21986985
17.
19.

An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions.

Zhang HL, Qin XJ, Cao DL, Zhu Y, Yao XD, Zhang SL, Dai B, Ye DW.

Asian J Androl. 2013 Mar;15(2):231-5. doi: 10.1038/aja.2012.116. Epub 2013 Feb 4.

20.

Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.

Sciarra A, Gentile V, Monti S, Dattilo C, Autran Gomez A, Salciccia S, Pannunzi LP, Toscano V, Di Silverio F.

Urol Int. 2008;80(1):68-73. doi: 10.1159/000111733. Epub 2008 Jan 18.

PMID:
18204237

Supplemental Content

Support Center